Inogen Inc (INGN) Director Ray Benjamin M. Anderson Sells 1,000 Shares

Inogen Inc (NASDAQ:INGN) Director Ray Benjamin M. Anderson sold 1,000 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $119.06, for a total transaction of $119,060.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $119,060. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of Inogen Inc (NASDAQ INGN) traded down $0.58 during trading on Wednesday, hitting $118.59. 195,745 shares of the company traded hands, compared to its average volume of 164,800. The company has a market cap of $2,460.00, a price-to-earnings ratio of 82.93, a price-to-earnings-growth ratio of 4.04 and a beta of 1.13. Inogen Inc has a 52 week low of $62.69 and a 52 week high of $130.05.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The company had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. During the same period in the prior year, the firm posted $0.25 EPS. Inogen’s revenue for the quarter was up 26.8% on a year-over-year basis. analysts predict that Inogen Inc will post 1.19 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in INGN. Sei Investments Co. grew its position in Inogen by 38.1% during the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after purchasing an additional 443 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Inogen by 0.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 71,356 shares of the medical technology company’s stock valued at $6,809,000 after purchasing an additional 655 shares during the last quarter. First Trust Advisors LP grew its position in Inogen by 1.6% during the 2nd quarter. First Trust Advisors LP now owns 29,726 shares of the medical technology company’s stock valued at $2,836,000 after purchasing an additional 459 shares during the last quarter. Rhumbline Advisers grew its position in Inogen by 0.5% during the 2nd quarter. Rhumbline Advisers now owns 32,122 shares of the medical technology company’s stock valued at $3,065,000 after purchasing an additional 174 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Inogen by 4.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 293,070 shares of the medical technology company’s stock valued at $27,964,000 after purchasing an additional 13,160 shares during the last quarter.

Several brokerages recently issued reports on INGN. BidaskClub lowered shares of Inogen from a “buy” rating to a “hold” rating in a research note on Tuesday, December 5th. Leerink Swann reiterated an “outperform” rating and issued a $120.00 price target (up from $115.00) on shares of Inogen in a research note on Wednesday, November 8th. Piper Jaffray Companies reiterated a “hold” rating and issued a $90.00 price target on shares of Inogen in a research note on Tuesday, September 12th. Needham & Company LLC increased their price target on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, November 8th. Finally, Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a research note on Thursday, November 9th. Four equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $103.14.

COPYRIGHT VIOLATION WARNING: “Inogen Inc (INGN) Director Ray Benjamin M. Anderson Sells 1,000 Shares” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/03/inogen-inc-ingn-director-ray-benjamin-m-anderson-sells-1000-shares.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply